Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05877508 · ClinicalTrials.gov registry record · Phase 2

Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

A Phase 2 study of Long COVID and Post-Acute COVID-19, sponsored by Michael Peluso, MD.

Active
Registry status
Phase 2
Development phase
36
Enrollment target
1
Study location

NCT05877508 is a Phase 2 study of Long COVID and Post-Acute COVID-19 that is active but no longer recruiting, run by Michael Peluso, MD. The registered enrollment target is 36 participants, below the 2,187-participant average among 50 other Long COVID trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05877508, a Phase 2 study of Long COVID and Post-Acute COVID-19, is active but no longer recruiting, sponsored by Michael Peluso, MD.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be able to be targeted by SARS-CoV-2 monoclonal antibodies (mAbs). This trial will study the safety and efficacy of AER002 to treat individuals with Long COVID in an adult population.

Conditions Studied

Long COVID Post-Acute COVID-19 Post-Acute Sequela of COVID-19

Interventions

  • OTHER Placebo
  • DRUG AER002

Study Locations (1)

California

  • UCSF/Zuckerberg San Francisco General Hospital - San Francisco

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2023-08-01
Est. Completion 2026-07-31
Phase Phase 2

Sponsor

Michael Peluso, MD

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05877508

The ClinicalTrials.gov registry entry for NCT05877508 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,187-participant average among 50 other Long COVID trials with a reported enrollment target (98% lower). The listed sponsor is Michael Peluso, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Long COVID appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05877508 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05877508 about?

NCT05877508 is a clinical study titled "Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)". Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be able to be targeted by SARS-CoV-2 monoclonal antibodies (mAbs). This trial will study the safety and...

What is the current status of trial NCT05877508?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2023-08-01. Estimated completion is 2026-07-31.

What conditions does trial NCT05877508 study?

This clinical trial studies the following conditions: Long COVID, Post-Acute COVID-19, Post-Acute Sequela of COVID-19.

What interventions are being tested in trial NCT05877508?

The interventions under investigation include: Placebo (OTHER), AER002 (DRUG).

Who is sponsoring clinical trial NCT05877508?

This trial is sponsored by Michael Peluso, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05877508 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Long COVID

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Long COVID

All registered trials for this condition

Post-Acute COVID-19

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.